Business
TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access
Mr. Camiolo brings to TScan demonstrated commercial readiness and cell therapy launch experienceWALTHAM, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the appointment of Stephen Camiolo as Senior Vice President, Market Access. Mr. Camiolo brings to TScan over 25 years of exper
About this update from Tscan Therapeutics, Inc.
[{"type":"image","alt":"TScan Therapeutics, Inc.","displaySize":"","headline":null,"caption":"TScan Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":88,"url":"https://media.zenfs.com/en/globenewswire.com/c363c98946cf506a90ed1ea98d7db5fd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oJd2gbDue06Bt1BDI6AStQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c363c98946cf506a90ed1ea98d7db5fd","width":300,"height":88}},"lazy":false},{"type":"text","content":"Mr. Camiolo brings to TScan demonstrated commercial readiness and cell therapy launch experience","length":96,"tagName":"p"},{"type":"text","content":"WALTHAM, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the appointment of Stephen Camiolo as Senior Vice President, Market Access. Mr. Camiolo brings to TScan over 25 years of experience in market access, reimbursement, pricing strategy, sales, marketing, and account management across the pharmaceutical and biotechnology industries.","length":557,"tagName":"p"},{"type":"text","content":"“We are delighted to welcome Stephen to TScan at this stage of growth for the Company,” said Gavin MacBeath, Ph.D., Chief Executive Officer. “His robust commercial leadership experience includes over 16 successful product launches across multiple disease areas, of which three were cell therapies. This expertise is invaluable as we prepare to launch a pivotal trial of TSC-101 to treat residual disease and prevent relapse in patients with AML, ALL, and MDS later this year and continue to advance enrollment in our PLEXI-T™ solid tumor program.”","length":547,"tagName":"p"},{"type":"text","content":"“I am eager to join TScan ahead of a truly transformative time for the Company, which is bolstered by the impressive progress achieved across its clinical-stage pipeline in the past year,” said Mr. Camiolo. “With multiple critical milestones on the horizon, I look forward to working closely with the team and using my cell therapy launch experience to support TScan in its mission to deliver life-changing TCR-T therapies to patients fighting a variety of heme and...